Courtney is the Chief Scientific Officer at Tizona Therapeutics, bringing to the role 30 years of experience in immunology and cancer research, drug development, as well as scientific strategy and leadership. She joined Tizona in 2015 to build the pipeline and research team needed to advance work critical to the Company’s strategy.

May 15, 2024 · Recent News. October 31, 2024 Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer

Culture and Benefits Striving to be the Best. The best teams are built by hiring the best people. Tizona cultivates a science-driven, creative, open, honest, optimistic and respectful corporate culture.

Pipeline Overview. Our oncology pipeline is focused on restoring and bolstering immune responses. Tizona is enrolling patients in two randomized arms within the ongoing Phase 1b clinical trial (NCT04485013) to evaluate either TTX-080 plus cetuximab and FOLFIRI or cetuximab and FOLFIRI alone in biomarker-defined metastatic colorectal cancer.